Therapy for Gaucher Disease: Don't Stop Thinking About Tomorrow
Overview
Affiliations
While enzyme replacement therapy for Gaucher disease has been widely used and appears to be an efficacious and safe treatment, this success should not be a reason for complacency. Other treatment strategies currently under consideration for patients with Gaucher disease include gene therapy, substrate reduction therapy and chaperone therapy. Furthermore, improvements in enzyme therapy could also have a significant clinical impact. Individuals with Gaucher disease and other lysosomal disorders will greatly benefit from continual refinement and optimization of the current therapy, as well as from the development of new treatment modalities that offer improvements in efficacy, cost, safety and availability.
Sgambato J, Park T, Miller D, Panicker L, Sidransky E, Lun Y Stem Cells Transl Med. 2015; 4(8):878-86.
PMID: 26062980 PMC: 4511143. DOI: 10.5966/sctm.2014-0213.
A high throughput glucocerebrosidase assay using the natural substrate glucosylceramide.
Motabar O, Goldin E, Leister W, Liu K, Southall N, Huang W Anal Bioanal Chem. 2011; 402(2):731-9.
PMID: 22033823 PMC: 3351006. DOI: 10.1007/s00216-011-5496-z.
Wang F, Song W, Brancati G, Segatori L J Biol Chem. 2011; 286(50):43454-64.
PMID: 22006919 PMC: 3234808. DOI: 10.1074/jbc.M111.274332.
Hematopoietic stem cell expansion and gene therapy.
Watts K, Adair J, Kiem H Cytotherapy. 2011; 13(10):1164-71.
PMID: 21999373 PMC: 3291512. DOI: 10.3109/14653249.2011.620748.
Type 1 Gaucher disease: significant disease manifestations in "asymptomatic" homozygotes.
Balwani M, Fuerstman L, Kornreich R, Edelmann L, Desnick R Arch Intern Med. 2010; 170(16):1463-9.
PMID: 20837833 PMC: 3098047. DOI: 10.1001/archinternmed.2010.302.